Haldol Decanoate

Haldol Decanoate is a prescription injectable suspension that contains haloperidol decanoate as the active ingredient. Formulated as a long‑acting intramuscular depot, it is used for maintenance therapy of psychotic disorders. Marketed in the European Union, this butyrophenone‑type typical antipsychotic blocks dopamine D2 receptors in the brain. It is administered by a healthcare professional to provide stable plasma levels over several weeks and ensures consistent therapeutic effect.

Haldol Decanoate is indicated for several psychiatric conditions where long‑acting antipsychotic therapy is preferred.

- Schizophrenia maintenance treatment – helps prevent relapse in patients stabilized on oral haloperidol. - Acute psychotic episodes when rapid control is needed and oral administration is not feasible. - Chronic psychotic disorders requiring monthly dosing to improve adherence. - Adjunctive therapy in patients with treatment‑resistant psychosis under specialist supervision. - Situations where oral antipsychotics cause significant side‑effects and a depot formulation is advantageous.

The safety profile of Haldol Decanoate includes both frequently observed and less common adverse reactions that clinicians monitor during treatment. These effects can vary in intensity based on dose, injection site, and individual susceptibility.

Common: - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Drowsiness or sedation, especially after the first injection. - Dry mouth, constipation, or blurred vision. - Weight gain or increased appetite. - Elevated prolactin levels that may cause menstrual irregularities, galactorrhea, or sexual dysfunction.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening condition. - Tardive dyskinesia, characterized by involuntary movements after prolonged use. - Severe hypotension or cardiac arrhythmias. - Severe allergic reactions such as anaphylaxis, presenting with rash, swelling, or breathing difficulty.

When prescribing Haldol Decanoate, clinicians consider several precautions to ensure safe and effective use.

- Assess patient history for cardiovascular disease, as the drug may affect heart rhythm. - Monitor for signs of extrapyramidal symptoms, especially during the first few months. - Evaluate liver and kidney function before initiating therapy and periodically thereafter. - Use caution in patients with a history of seizures or neuroleptic malignant syndrome. - Discuss potential pregnancy and lactation risks with women of childbearing age. - Ensure proper injection technique to avoid muscle injury or local reactions.

Haldol Decanoate can interact with other medicines, altering its efficacy or increasing the risk of adverse effects.

Avoid: - Concurrent use with other dopamine antagonists, which may intensify extrapyramidal side effects. - Co‑administration with strong CYP3A4 inhibitors, potentially raising haloperidol levels. - Combining with QT‑prolonging agents, increasing the risk of cardiac arrhythmias. - Avoid simultaneous use with other long‑acting injectable antipsychotics, as overlapping pharmacodynamics may increase toxicity.

Use with caution: - Concurrent use with CNS depressants such as benzodiazepines; monitor for enhanced sedation. - Co‑administration with anticholinergic drugs; may mask early signs of extrapyramidal symptoms. - Use with caution in patients receiving lithium; monitor for neurotoxicity. - Use with caution when prescribing with antihypertensive agents; monitor blood pressure due to possible additive hypotensive effects.